Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma

BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:ERJ Open Res
Main Authors: Castro, Mario, Rabe, Klaus F., Corren, Jonathan, Pavord, Ian D., Katelaris, Constance H., Tohda, Yuji, Zhang, Bingzhi, Rice, Megan S., Maroni, Jaman, Rowe, Paul, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Graham, Neil M.H., Teper, Ariel
Format: Artigo
Sprog:Inglês
Udgivet: European Respiratory Society 2020
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6983496/
https://ncbi.nlm.nih.gov/pubmed/32010719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00204-2019
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker